Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.
3.

Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.

Enseleit F, Hürlimann D, Lüscher TF.

J Cardiovasc Pharmacol. 2001 Apr;37 Suppl 1:S21-30. Review.

PMID:
11392475
4.

Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.

Ferrari R, Fox K.

Drugs. 2009;69(3):265-77. doi: 10.2165/00003495-200969030-00003. Review.

PMID:
19275271
5.

Endothelial function and bradykinin in humans.

Hornig B, Drexler H.

Drugs. 1997;54 Suppl 5:42-7. Review.

PMID:
9429844
6.

Nitric oxide, angiotensin II, and hypertension.

Zhou MS, Schulman IH, Raij L.

Semin Nephrol. 2004 Jul;24(4):366-78. Review.

PMID:
15252776
7.

Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.

Higashi Y, Chayama K, Yoshizumi M.

Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr;3(2):133-48. Review.

PMID:
15853700
8.
9.

Blockade of endothelial enzymes: new therapeutic targets.

López-Jaramillo P, Casas JP.

J Hum Hypertens. 2002 Mar;16 Suppl 1:S100-3. Review.

10.

Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease.

Lyons D.

Int J Cardiol. 1997 Dec 31;62 Suppl 2:S101-9. Review.

PMID:
9488201
11.

Combination of ACE inhibitors and calcium antagonists: a logical approach.

Ruschitzka FT, Noll G, Lüscher TF.

J Cardiovasc Pharmacol. 1998;31 Suppl 2:S5-16. Review.

PMID:
9605596
12.
13.

Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models.

Bakris GL.

Am J Hypertens. 2001 Aug;14(8 Pt 2):264S-269S. Review.

PMID:
11497207
14.

Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis.

Schulman IH, Zhou MS, Raij L.

Curr Hypertens Rep. 2005 Feb;7(1):61-7. Review.

PMID:
15683588
15.

Protection of endothelial function: targets for nutritional and pharmacological interventions.

Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G, Lüscher TF.

J Cardiovasc Pharmacol. 2006;47 Suppl 2:S136-50; discussion S172-6. Review.

PMID:
16794451
16.

Restoring the dysfunctional endothelium.

Osto E, Coppolino G, Volpe M, Cosentino F.

Curr Pharm Des. 2007;13(10):1053-68. Review.

PMID:
17430168
17.
18.

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin.

Kitakaze M, Asanuma H, Funaya H, Node K, Takashima S, Sanada S, Asakura M, Ogita H, Kim J, Hori M.

J Am Coll Cardiol. 2002 Jul 3;40(1):162-6.

19.

Calcium channel blockers, endothelial dysfunction, and combination therapy.

Schulman IH, Zachariah M, Raij L.

Aging Clin Exp Res. 2005 Aug;17(4 Suppl):40-5. Review.

PMID:
16640172
20.

Angiotensin II, nitric oxide, and end-organ damage in hypertension.

Bataineh A, Raij L.

Kidney Int Suppl. 1998 Dec;68:S14-9. Review.

PMID:
9839277

Supplemental Content

Support Center